Q1 Earnings Forecast for Alumis Issued By Leerink Partnrs

Alumis Inc. (NASDAQ:ALMS) – Analysts at Leerink Partnrs issued their Q1 2025 EPS estimates for Alumis in a research report issued to clients and investors on Sunday, March 23rd. Leerink Partnrs analyst T. Smith anticipates that the company will post earnings per share of ($1.46) for the quarter. The consensus estimate for Alumis’ current full-year earnings is ($8.51) per share.

Several other analysts also recently weighed in on ALMS. Cantor Fitzgerald reissued an “overweight” rating on shares of Alumis in a research note on Thursday, March 20th. HC Wainwright restated a “buy” rating and set a $15.00 target price on shares of Alumis in a report on Wednesday. Finally, Oppenheimer initiated coverage on Alumis in a research note on Thursday, January 30th. They issued an “outperform” rating and a $32.00 price target on the stock. Seven equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $26.00.

Alumis Stock Performance

Shares of ALMS opened at $4.92 on Tuesday. Alumis has a fifty-two week low of $3.18 and a fifty-two week high of $13.53. The firm has a 50 day moving average price of $5.49 and a 200-day moving average price of $8.40.

Institutional Investors Weigh In On Alumis

Institutional investors and hedge funds have recently bought and sold shares of the business. Charles Schwab Investment Management Inc. bought a new position in shares of Alumis during the third quarter valued at approximately $1,160,000. BNP Paribas Financial Markets bought a new position in Alumis in the 3rd quarter worth $27,000. MetLife Investment Management LLC bought a new stake in shares of Alumis during the 3rd quarter valued at about $89,000. Maven Securities LTD increased its position in shares of Alumis by 100.0% during the third quarter. Maven Securities LTD now owns 50,000 shares of the company’s stock valued at $534,000 after buying an additional 25,000 shares during the period. Finally, Samsara BioCapital LLC bought a new position in Alumis in the third quarter worth about $34,886,000.

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.